VBI-2902

VBI-2902

VBI-2902

Vaccine candidate against COVID-19


N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]

Quick Facts Vaccine description, Target ...

History

In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[2] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[2][3][4] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[5]


References

  1. Philippidis A (1 November 2021). "Six Up-and-Coming COVID-19 Vaccines". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 December 2021.
  2. "VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 March 2022.
  3. Curran M, Sali D, Kovessy P (August 2020). "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. Archived from the original on 2 May 2021. Retrieved 22 March 2021.

Share this article:

This article uses material from the Wikipedia article VBI-2902, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.